ReviewIndian journal of ophthalmology2026
Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of retinal and choroidal neovascularization, as well as macular edema (ME), in retinal disorders such as diabetic retinopathy, retinal vein occlusion (RVO), and age-related macular degeneration (ARMD). The advent of intravitreal anti-VEGF therapy has revolutionized their management. More recently, these agents have been explored in several other retinal pathologies characterized by secondary neovascularization, either in vascular or non-vascular disorders. This review summarizes current evidence on the role of anti-VEGF agents in retinal disorders other than ARMD, including central serous chorioretinopathy (CSCR), macular telangiectasia type 2 (MacTel), choroidal osteoma, retinopathy of prematurity (ROP), tubercular granuloma, inherited retinal dystrophies, Coats' disease, angioid streaks, and retinal vasoproliferative tumors (RVPTs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.